NVNO Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 16.00%

Insider Buying (Last 12 Months): $50,288.60

Insider Selling (Last 12 Months): $0.00

enVVeno Medical Insider Trading History Chart

enVVeno Medical Share Price & Price History

^$2.64

▲ +0.164 (6.61%)

As of 04/4/2025 11:01 AM ET

Days: 30 | 90 | 365

enVVeno Medical Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/31/2024	Robert Gray	Director	Buy	3,500	$2.94	$10,290.00	11,155
12/24/2024	Sanjay Shrivastava	Director	Buy	5,400	$2.90	$15,660.00	9,288
12/19/2024	Matthew Jenusaitis	Director	Buy	9,620	$2.53	$24,338.60	16,545
3/13/2024	Hamed Alavi	CTO	Sell	8,334	$6.22	$51,837.48
8/16/2022	Francis Duhay	Director	Buy	7,751	$6.14	$47,591.14	20,911
6/30/2022	Sanjay Shrivastava	Director	Buy	1,000	$3.85	$3,850.00	3,888
6/27/2022	Robert Andrew Berman	CEO	Buy	2,500	$3.80	$9,500.00	210,236

See Full Table

SEC Filings (Institutional Ownership Changes) for enVVeno Medical (NASDAQ:NVNO)

34.71% of enVVeno Medical stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

enVVeno Medical Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
2/17/2025	Alyeska Investment Group L.P.	209,180	$0.63M	0.0%	-50.8%	1.193%
2/14/2025	Jane Street Group LLC	18,502	$56K	0.0%	N/A	0.105%
2/14/2025	Northern Trust Corp	56,725	$0.17M	0.0%	+68.3%	0.323%
2/14/2025	Dimensional Fund Advisors LP	16,242	$49K	0.0%	-51.1%	0.093%
2/14/2025	Altium Capital Management LLC	310,000	$0.94M	0.3%	+29.8%	1.767%
2/13/2025	Marshall Wace LLP	48,818	$0.15M	0.0%	N/A	0.278%
2/12/2025	Geode Capital Management LLC	181,737	$0.55M	0.0%	+20.6%	1.036%
2/12/2025	National Bank of Canada FI	20,000	$60K	0.0%	N/A	0.114%
2/12/2025	JPMorgan Chase & Co.	270,041	$0.82M	0.0%	N/A	1.540%
2/11/2025	Virtu Financial LLC	28,533	$86K	0.0%	N/A	0.163%
1/31/2025	Sanctuary Advisors LLC	12,000	$39K	0.0%	N/A	0.068%
1/17/2025	Westside Investment Management Inc.	205,025	$0.62M	0.1%	+132.0%	1.169%
1/15/2025	Fermata Advisors LLC	35,706	$0.11M	0.0%	+18.1%	0.204%
11/20/2024	Westside Investment Management Inc.	88,375	$0.30M	0.1%	+128.0%	0.504%
11/19/2024	Hohimer Wealth Management LLC	85,000	$0.29M	0.1%	N/A	0.485%
11/16/2024	Geode Capital Management LLC	150,676	$0.51M	0.0%	+7.8%	0.859%
11/15/2024	Maven Securities LTD	87,880	$0.30M	0.0%	N/A	0.501%
11/14/2024	Corsair Capital Management L.P.	116,000	$0.39M	0.1%	N/A	0.661%
8/20/2024	Nantahala Capital Management LLC	477,855	$2.51M	0.1%	-3.6%	3.585%
7/17/2024	Westside Investment Management Inc.	38,762	$0.20M	0.0%	+933.7%	0.291%
7/13/2024	Fermata Advisors LLC	30,949	$0.16M	0.0%	+33.4%	0.232%
5/16/2024	Kingdon Capital Management L.L.C.	653,870	$3.56M	0.4%	+5.6%	4.905%
5/15/2024	Quadrature Capital Ltd	18,872	$0.10M	0.0%	N/A	0.142%
5/10/2024	Acadian Asset Management LLC	6,825	$37K	0.0%	N/A	0.051%
5/10/2024	Vanguard Group Inc.	573,955	$3.12M	0.0%	+70.6%	4.310%
5/3/2024	RIA Advisory Group LLC	43,666	$0.24M	0.1%	N/A	0.328%
5/1/2024	Janney Montgomery Scott LLC	34,140	$0.19M	0.0%	N/A	0.256%
4/12/2024	Fermata Advisors LLC	23,198	$0.13M	0.0%	+42.1%	0.174%
3/18/2024	Kingdon Capital Management L.L.C.	619,180	$3.18M	0.4%	+182.5%	4.648%
2/26/2024	Perceptive Advisors LLC	623,315	$3.20M	0.1%	-20.3%	4.680%
2/13/2024	Armistice Capital LLC	436,000	$2.24M	0.0%	N/A	3.273%
1/19/2024	Fermata Advisors LLC	16,325	$84K	0.0%	+37.8%	0.123%
11/7/2023	Fermata Advisors LLC	11,850	$64K	0.0%	N/A	0.089%
7/19/2023	Arthur M. Cohen & Associates LLC	14,000	$43K	0.0%	-41.7%	0.148%
11/14/2022	UBS Oconnor LLC	149,720	$0.94M	0.0%	+26.8%	1.581%
7/26/2022	Sepio Capital LP	10,800	$41K	0.0%	N/A	0.114%
7/18/2022	Arthur M. Cohen & Associates LLC	24,000	$91K	0.0%	+60.0%	0.253%
5/11/2022	ACT Capital Management LLC	401,200	$2.56M	2.7%	+52.8%	4.237%
2/15/2022	Kingdon Capital Management L.L.C.	219,180	$1.44M	0.2%	N/A	2.315%
2/14/2022	Perceptive Advisors LLC	781,615	$5.15M	0.1%	N/A	8.255%
2/3/2022	ACT Capital Management LLC	262,500	$1.73M	1.3%	N/A	2.772%
1/24/2022	Arthur M. Cohen & Associates LLC	14,000	$92K	0.0%	N/A	0.148%
8/17/2021	Worth Venture Partners LLC	82,886	$0.57M	0.2%	-17.7%	0.974%
8/16/2021	State Street Corp	20,200	$0.14M	0.0%	N/A	0.237%
8/13/2021	Geode Capital Management LLC	63,753	$0.44M	0.0%	+75.8%	0.749%
8/13/2021	Vanguard Group Inc.	258,680	$1.78M	0.0%	+483.6%	3.038%
8/12/2021	AIGH Capital Management LLC	346,885	$2.38M	0.4%	-19.1%	4.074%
5/21/2021	Citadel Advisors LLC	11,512	$77K	0.0%	N/A	0.135%
5/19/2021	Worth Venture Partners LLC	100,714	$0.67M	0.3%	N/A	1.183%
5/18/2021	Millennium Management LLC	23,567	$0.16M	0.0%	N/A	0.277%
5/18/2021	Citadel Advisors LLC	11,512	$77K	0.0%	N/A	0.135%
5/18/2021	Jane Street Group LLC	21,745	$0.15M	0.0%	N/A	0.255%
5/14/2021	Dimensional Fund Advisors LP	10,821	$72K	0.0%	N/A	0.127%
5/12/2021	Northern Trust Corp	15,360	$0.10M	0.0%	N/A	0.181%
5/12/2021	Geode Capital Management LLC	36,268	$0.24M	0.0%	N/A	0.426%
5/12/2021	UBS Group AG	17,061	$0.11M	0.0%	+1,326.5%	0.201%
2/24/2021	Virtu Financial LLC	26,107	$0.23M	0.0%	N/A	1.008%

Data available starting January 2016

See Full Table

enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company's lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial.

Today's Range

Now: $2.64

$2.40

$2.49

50 Day Range

MA: $3.12

$2.48

$3.82

52 Week Range

Now: $2.64

$2.43

$6.48

Volume

46,487 shs

Average Volume

107,733 shs

Market Capitalization

$46.37 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.04

Who are the company insiders with the largest holdings of enVVeno Medical?: enVVeno Medical's top insider investors include:
Matthew Jenusaitis (Director)
Robert Gray (Director)
Sanjay Shrivastava (Director)
Hamed Alavi (CTO)
Learn More about top insider investors at enVVeno Medical.